Hormone Receptor-positive Breast Cancer
Showing 1 - 25 of >10,000
Musculoskeletal Syndrome Trial in Minneapolis (CBD-dominant, THC dominant)
Recruiting
- Musculoskeletal Syndrome
- CBD-dominant
- THC dominant
-
Minneapolis, MinnesotaUniversity of Minnesota
Jun 28, 2023
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
Breast Cancer Trial in Boston (Acupuncture, Usual Care)
Active, not recruiting
- Breast Cancer
- Acupuncture
- Usual Care
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 21, 2022
Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)
Recruiting
- Hormone Receptor-positive Breast Cancer
-
Tampa, FloridaMoffitt Cancer Center
Dec 30, 2022
Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian
Not yet recruiting
- Hormone-receptor-positive Breast Cancer
- +3 more
- Aromatase inhibitor
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023
Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer Trial in Boston
Completed
- Breast Cancer Stage IV
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 21, 2022
Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)
Active, not recruiting
- Breast Cancer
- Pembrolizumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 22, 2022
Hot Flashes, Breast Cancer, Acupuncture Trial in Nanjing (Acupuncture treatment, Sham acupuncture treatment)
Not yet recruiting
- Hot Flashes
- +2 more
- Acupuncture treatment
- Sham acupuncture treatment
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Traditional Chinese Medcine
Nov 11, 2022
Hot Flashes, Breast Cancer, Acupuncture Trial in Nanjing (Acupuncture treatment, Sham Acupuncture treatment)
Not yet recruiting
- Hot Flashes
- +2 more
- Acupuncture treatment
- Sham Acupuncture treatment
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Traditional Chinese Medcine
Jul 19, 2022
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,
Not yet recruiting
- Locoregional Recurrence
- +2 more
- Ribociclib
- +4 more
- (no location specified)
Jul 18, 2022
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab
Recruiting
- HER2-positive Breast Cancer
- +17 more
- ALX148
- Fam-Trastuzumab Deruxtecan-Nxki
-
Chicago, Illinois
- +1 more
May 19, 2023
Breast Cancer, Breast Carcinoma, Cancer of Breast Trial in Saint Louis, Lincoln (Palbociclib, Letrozole, Fulvestrant)
Active, not recruiting
- Breast Cancer
- +3 more
- Palbociclib
- +7 more
-
Saint Louis, Missouri
- +1 more
Jul 20, 2022
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,
Not yet recruiting
- Breast Cancer Invasive
- +3 more
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023
Breast Cancer Female, Hormone-receptor-positive Breast Cancer Trial in Lisboa (Brief Physical Activity Counselling, Structured
Recruiting
- Breast Cancer Female
- Hormone-receptor-positive Breast Cancer
- Brief Physical Activity Counselling
- Structured Exercise Program
-
Lisboa, PortugalUniversidade Lusófona, Campo Grande 376
May 5, 2023
Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer
Active, not recruiting
- Hormone-receptor-positive Breast Cancer
- +2 more
- No drug
-
Cambridge, MassachusettsConcertAI database
Sep 8, 2023
Breast Cancer Trial in Boston (Eribulin Mesylate, Pembrolizumab)
Active, not recruiting
- Breast Cancer
- Eribulin Mesylate
- Pembrolizumab
-
Boston, Massachusetts
- +2 more
Apr 18, 2022
Hormone Receptor-positive Breast Cancer Trial (LACUDY)
Not yet recruiting
- Hormone Receptor-positive Breast Cancer
- (no location specified)
Dec 6, 2022
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial
Not yet recruiting
- Hormone Receptor-positive Breast Cancer
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Oct 5, 2022
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial
Withdrawn
- Anatomic Stage 0 Breast Cancer AJCC v8
- +28 more
- Carbon Dioxide Fractional Laser
- Questionnaire Administration
- (no location specified)
Jan 5, 2023
Hormone Receptor Positive Malignant Tumor of Breast Trial in United States (RAD140)
Completed
- Hormone Receptor Positive Malignant Neoplasm of Breast
-
New Haven, Connecticut
- +4 more
Aug 16, 2022
Study of Screening Brain MRIs in Stage IV Breast Cancer
Recruiting
- Triple Negative Breast Cancer
- +2 more
- Magnetic Resonance Imaging
-
Tampa, FloridaMoffitt Cancer Center
Sep 30, 2022
Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma Trial in Boston
Not yet recruiting
- Male Breast Cancer
- +2 more
- Tamoxifen
- +3 more
-
Boston, Massachusetts
- +1 more
Aug 12, 2022